<DOC>
	<DOCNO>NCT02913482</DOCNO>
	<brief_summary>Open-label , multi-center clinical study ass safety , tolerability , pharmacokinetic , pharmacodynamics , efficacy RO7034067 infant Type 1 spinal muscular atrophy ( SMA ) . The study consist two part , exploratory dose find part ( Part 1 ) confirmatory part ( Part 2 ) investigate RO7034067 24-months dose select Part 1 .</brief_summary>
	<brief_title>A Study Investigate Safety , Tolerability , Pharmacokinetics , Pharmacodynamics Efficacy RO7034067 Infants With Type1 Spinal Muscular Atrophy ( Firefish )</brief_title>
	<detailed_description />
	<mesh_term>Atrophy</mesh_term>
	<mesh_term>Muscular Atrophy , Spinal</mesh_term>
	<mesh_term>Muscular Atrophy</mesh_term>
	<criteria>Clinical history , sign symptom attributable Type 1 SMA onset 28 day prior age 3 month Gestational age 37 42 week Confirmed diagnosis 5qautosomal recessive SMA Participants two survival motor neuron 2 ( SMN2 ) gene copy , confirm central test Body weight great equal ( &gt; = ) third percentile age , use appropriate countryspecific guideline Receiving adequate nutrition hydration ( without gastrostomy ) time screen , opinion Investigator Adequately recover acute illness time screen consider wellenough participate opinion Investigator Concomitant previous participation investigational drug device study within 90 day prior screen 5 halflives , whichever longer Concomitant previous participation SMN2 target antisense oligonucleotide SMN2 splice modifier gene therapy study Any history cell therapy Hospitalization pulmonary event within last 2 month , plan time screen Presence clinically relevant electrocardiogram ( ECG ) abnormality study drug administration Unstable gastrointestinal , renal , hepatic , endocrine cardiovascular system diseases Participants require invasive ventilation tracheostomy Participants require awake noninvasive ventilation awake hypoxemia ( arterial oxygen saturation less [ &lt; ] 95 percent [ % ] ) without ventilator support Participants history respiratory failure severe pneumonia , fully recover pulmonary function time screen Multiple fixed contracture and/or hip subluxation dislocation birth Presence nonSMA related concurrent syndrome diseases Any major illness within one month screen examination febrile illness within one week prior screen first dose administration Any inhibitor cytochrome P450 ( CYP ) 3A4 and/or Organic Cation Transporter 2 ( OCT2 ) multidrug toxin extrusion ( MATE ) substrates take within 2 week and/or inducer CYP3A4 take within 4 week ( within 5times elimination halflife , whichever long ) prior dose participant ( mother , breastfeed infant ) take nutrient know modulate CYP3A activity know flavin contain monooxygenase ( FMO ) 1 FMO3 inhibitor substrates Prior use , anticipate need hydroxychloroquine , vigabatrin , retigabine , drug know cause retinal toxicity study Recent history ( le 6 month ) ophthalmic disease would interfere conduct study assess ophthalmologist</criteria>
	<gender>All</gender>
	<minimum_age>1 Month</minimum_age>
	<maximum_age>7 Months</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>